Literature DB >> 20616297

Chronic kidney disease in primary care.

Duaine D Murphree1, Sarah M Thelen.   

Abstract

Because chronic kidney disease is a growing health concern, family physicians must be equipped to care for this unique patient population. Diabetes mellitus and hypertension, which are commonly addressed in the office setting, are the largest contributors to chronic kidney disease; therefore, these risk factors should be tightly controlled and these patients should be screened closely for signs of renal damage. The National Kidney Foundation recommends that screening include determination of the glomerular filtration rate (GFR) and assessment for the presence of proteinuria. Once the diagnosis of chronic kidney disease is established (by the presence of persistent kidney damage or a GFR <60 mL/min/1.73m(2) for at least 3 months), the etiology of chronic kidney disease needs to be elucidated. Often the etiology can be determined by history alone; however, reversible causes of chronic kidney disease should be considered in all patients. Regardless of the underlying etiology of the chronic kidney disease, the family physician can make a significant impact in slowing the progression of chronic kidney disease through strict blood pressure control, tight glycemic control, reduction in the degree of proteinuria, and smoking cessation. All chronic kidney disease patients are at significantly increased risk of cardiovascular events; therefore, additional cardiovascular risk factors such as hyperlipidemia should be managed aggressively. Assessment for the complications of chronic kidney disease, including anemia, bone metabolism abnormalities, metabolic acidosis, and malnourishment, should be assessed once the GFR declines below 60 mL/min/1.73m(2) (stage 3). Early screening and treatment of these complications can prevent the development of further sequelae and should not be delayed until referral to nephrology. Appropriate counseling and health maintenance is also needed for this patient population and should be given by the family physician involved in the patient's care.

Entities:  

Mesh:

Year:  2010        PMID: 20616297     DOI: 10.3122/jabfm.2010.04.090129

Source DB:  PubMed          Journal:  J Am Board Fam Med        ISSN: 1557-2625            Impact factor:   2.657


  11 in total

1.  Safety and Efficacy of A High Performance Graphene-Based Magnetic Resonance Imaging Contrast Agent for Renal Abnormalities.

Authors:  Shruti Kanakia; Jimmy Toussaint; Praveen Kukarni; Stephen Lee; Sayan Mullick Chowdhury; Slah Khan; Sandeep K Mallipattu; Kenneth R Shroyer; William Moore; Balaji Sitharaman
Journal:  Graphene Technol       Date:  2016-08-03

Review 2.  Elderly patients with community-acquired pneumonia: optimal treatment strategies.

Authors:  Ulrich Thiem; Hans-Jürgen Heppner; Ludger Pientka
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

3.  Acute Care QUAliTy in chronic Kidney disease (ACQUATIK): a prospective cohort study exploring outcomes of patients with chronic kidney disease.

Authors:  Julia J Arnold; Manvir Hayer; Adnan Sharif; Irena Begaj; Mohammed Tabriez; David Bagnall; Daniel Ray; Ciaron Hoye; Masood Nazir; Mary Dutton; Lesley Fifer; Katie Kirkham; Don Sims; Jonathan N Townend; Paramjit S Gill; Indranil Dasgupta; Paul Cockwell; Charles J Ferro
Journal:  BMJ Open       Date:  2015-05-03       Impact factor: 2.692

4.  Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.

Authors:  Khai P Ng; Poorva Jain; Paramjit S Gill; Gurdip Heer; Jonathan N Townend; Nick Freemantle; Sheila Greenfield; Richard J McManus; Charles J Ferro
Journal:  BMJ Open       Date:  2016-02-25       Impact factor: 2.692

5.  Screening for Chronic Kidney Disease in Adult Males in Vojvodina: A Cross-sectional Study.

Authors:  Velibor Čabarkapa; Branislava Ilinčić; Mirjana Đerić; Isidora Radosavkić; Mirko Šipovac; Jan Sudji; Veljko Petrović
Journal:  J Med Biochem       Date:  2017-04-22       Impact factor: 3.402

6.  Anaemia among primary care patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD): a multicentred cross-sectional study.

Authors:  Iliza Idris; Hizlinda Tohid; Noor Azimah Muhammad; Mohd Radzniwan A Rashid; Azainorsuzila Mohd Ahad; Norsiah Ali; Naemah Sharifuddin; Junita Harizon Aris
Journal:  BMJ Open       Date:  2018-12-22       Impact factor: 2.692

7.  The prevalence of chronic kidney disease in a primary care setting: a Swiss cross-sectional study.

Authors:  Yuki Tomonaga; Lorenz Risch; Thomas D Szucs; Patrice M Ambühl; Patrice M Ambuehl
Journal:  PLoS One       Date:  2013-07-03       Impact factor: 3.240

8.  Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.

Authors:  Khai P Ng; Poorva Jain; Gurdip Heer; Val Redman; Odette L Chagoury; George Dowswell; Sheila Greenfield; Nick Freemantle; Jonathan N Townend; Paramjit S Gill; Richard J McManus; Charles J Ferro
Journal:  Trials       Date:  2014-05-06       Impact factor: 2.279

9.  The relationship of ADC values of renal parenchyma with CKD stage and serum creatinine levels.

Authors:  Kadihan Yalçin-Şafak; Muhammet Ayyildiz; Sacide Yekta Ünel; Neslihan Umarusman-Tanju; Ahmet Akça; Tamer Baysal
Journal:  Eur J Radiol Open       Date:  2015-12-09

10.  Alcohol use disorder tied to development of chronic kidney disease: A nationwide database analysis.

Authors:  Chi-Syuan Pan; Teressa Reanne Ju; Chi Chan Lee; Yu-Pei Chen; Chung-Y Hsu; Dong-Zong Hung; Wei-Kung Chen; I-Kuan Wang
Journal:  PLoS One       Date:  2018-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.